Core Insights - CERo Therapeutics Holdings, Inc. is advancing its Phase 1 clinical trial of CER-1236 for acute myeloid leukemia (AML) at the Colorado Blood Cancer Institute, with patient enrollment currently underway and initial dosing expected by June 2025 [1][2][3] Company Overview - CERo is an innovative immunotherapy company focused on engineered T cell therapeutics that utilize phagocytic mechanisms to enhance cancer treatment [1][3] - The company’s proprietary T cell engineering approach aims to integrate characteristics of both innate and adaptive immunity, potentially offering greater therapeutic applications than current CAR-T therapies [3] Clinical Trial Details - The Phase 1/1b study is designed to evaluate the safety and preliminary efficacy of CER-1236 in patients with relapsed/refractory AML, measurable residual disease, or TP53 gene mutations [2] - The trial will consist of a dose escalation phase to determine the highest tolerated dose, followed by an expansion phase to assess safety and efficacy [2] - Primary outcome measures include the incidence of adverse events, dose-limited toxicities, overall response rate, complete response, composite complete response, and measurable residual disease [2] Expert Commentary - Dr. Yazan Migdady from the Colorado Blood Cancer Institute highlighted the potential of chimeric engulfment receptor technology in improving treatment outcomes for AML patients [2]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 As filed with the Securities and Exchange Commission on April 10, 2024 Registration No. 333- CERO THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) | Delaware | 2836 | 81-4182129 | | --- | --- | --- | | (State or other jurisdiction of | (Primary Standard Industrial | (I.R.S. Employer | | incorporation or organization) | Classification Code ...

As filed with the Securities and Exchange Commission on April 10, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CERO THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) | Delaware | 2836 | 81-4182129 | | --- | --- | --- | | (State or other jurisdiction of | (Primary Standard Industrial | (I.R.S. Employer | | incorporation or organization) | Classification Code ...